KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income: 2017-2025

Historic Net Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Net Income rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 139.30%. This contributed to the annual value of -$73.9 million for FY2024, which is 51.55% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Net Income of $18.1 million as of Q3 2025, which was down 49.08% from $35.6 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Net Income's 5-year high stood at $35.6 million during Q2 2025, with a 5-year trough of -$240.1 million in Q2 2022.
  • Its 3-year average for Net Income is -$4.0 million, with a median of $16.8 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Amneal Pharmaceuticals' Net Income was 1,135.41% (2023), while the steepest drop was 1,495.08% (2023).
  • Amneal Pharmaceuticals' Net Income (Quarterly) stood at -$20.4 million in 2021, then spiked by 71.33% to -$5.9 million in 2022, then plummeted by 1,495.08% to -$93.4 million in 2023, then soared by 77.75% to -$20.8 million in 2024, then surged by 54.22% to $18.1 million in 2025.
  • Its Net Income was $18.1 million in Q3 2025, compared to $35.6 million in Q2 2025 and $24.6 million in Q1 2025.